Welcome and Introduction to Vi3C

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Lymphoma

The ASCO Post Staff

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Mark J. Ratain, MD, of the University of Chicago, talks about why ibrutinib—which can lead to cardiotoxicities—should be studied at a lower dose for patients with chronic lymphocytic leukemia. Data suggest a reduced dose may prevent dose interruption due to adverse events and may have a better therapeutic index.

Oct

Today In Oncology

Welcome and Introduction to Vi3C

Related Videos

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Physician-Complementing Artificial Intelligence in Oncology

Zenocutuzumab Potential Explored in NRG1 Cholangiocarcinoma

Preneoplastic and Neoplastic Small Lymphocytic Proliferations

AI-Enhanced PACT as a Noninvasive Breast Imaging Alternative

Routine AI Assistance May Lead to Loss of Skills in Endoscopists, Study Shows